DPS References
Therapeutic/ | Title | Journal | Conference |
|---|---|---|---|
Myeloid | Novel Digital Pathology Tools for Exploring Role of Myeloid Cells in Modulating Next Generation Immunotherapies |
| AACR |
MSI High Tumor | DNA damage response assessment after WRN inhibition in MSI high tumors: mIF assays validation for preclinical and clinical evaluation |
| NIBR ONC Retreat |
DLBCL | Tissue-based Biomarker Analysis of DLBCL using Multiplex Immunofluorescence AQUA (automated quantitative analysis) algorithms |
| AACR |
Melanoma | Tumor-infiltrating B cells play a role in determining clinical outcome after BRAF and MEK inhibition | Clinical Cancer Research |
|
Solid tumor | Exploring the interplay between TAM, PD-L1 and immunosuppressive molecules by a novel multiplex immunofluorescence assay in cancer immunotherapy trials |
| AACR |
RCC | Clinical features and multiplatform molecular analysis assist in understanding patient response to anti-PD-1/PD-L1 in renal cell carcinoma | Cancers |
|
Solid tumor | Novel Approach for Profiling Immune-Tumor Cell Interactions and Mutations in the Same Tumor Section by Multiplex Immunohistochemistry and NGS in Immuno-Oncology Trials |
| SITC |
Solid tumor | Pathologists Enhance Interpretation of Automated Multiplex Immunohistochemistry Assays in Cancer Immunotherapy Trials |
| SITC |
Breast | MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC | JCI Insight |
|
GBM | Predictive Evaluation of Quantitative Spatial Profiling of the Tumor Microenvironment by Multiplex Immunofluorescence in Recurrent Glioblastoma Treated with PD-1 Inhibitors |
| ASCO |
Solid tumor | Immunophenotyping Tumors by Novel Multiplex Immunofluorescence and AQUA (Automated Quantitative Analyses) Algorithms to Guide Development of Immunotherapies |
| AACR |
Solid Tumor | Immuno-Oncology Biomarkers Identified by Novel Digital Pathology Approaches |
| MarketsandMarkets Biomarker and Companion Diagnostics |
Breast | The immune landscape of residual triple-negative breast cancers after neoadjuvant chemotherapy. |
| SABCS |
SCLC | Improved prognosis and increased tumor infiltrating lymphocytes in small cell lung cancer patients with neurologic paraneoplastic syndromes. | Journal of Thoracic Oncology | ASCO |
Breast | MEK activation modulates immunosuppressive MDSC and metabolic programs in TNBC |
| AACR |
Breast | Molecular characterization of residual triple-negative breast cancers after neoadjuvant chemotherapy identifies immune composition and features associated with clinical outcome |
| AACR |
DLBCL | PD-1/PD-L1 expression and interaction in the microenvironment of DLBCL by Quantitative Immunofluorescent Analysis. | Modern Pathology | ASCO |
Solid Tumors | Tumor-specific major histocompatibility complex class II (MHC-II) expression drives a unique pattern of adaptive resistance to immunotherapy through MHC-II receptor engagement. | Journal of Clinical Investigations | ASCO |
Melanoma | Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of anti-PD-1 Therapies in Metastatic Melanoma | Clinical Cancer Research | ASCO |
Melanoma | Characterization of the tumor immune microenvironment following ipilimumab and IFNα2b neoadjuvant therapy in melanoma |
| SITC |
SCCHN | IDO/HLA-DR expression and tumor mutational burden are complementary predictive biomarkers of anti-PD-1 immunotherapy in squamous cell carcinoma of head and neck |
| SITC |
Melanoma & NSCLC | Development of clinical-grade multiplex F-IHC assays to quantify spatial distribution of PD-L1. |
| NIBR Onc Retreat |
Multiple | Multiplex FIHC and AQUA Analysis for I-O Clinical Trials: Challenges & Successes |
| NHS |
NSCLC | Tumor PD-L1 heterogeneity in non-small cell lung cancer: Does biopsy size and volume matter? |
| ASCO |
NSCLC | PD-1/PD-L1 Interaction and CD25/FOXP3+ T cells Predict Survival Benefit from Adjuvant Chemotherapy in Early Stage Non–Small-Cell Lung Cancer (ES-NSCLC) |
| ASCO |
DLBCL | Biomarker analysis of tisagenlecleucel pre-infusion biopsies of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) |
| EHA |
SCLC | Clinical Outcomes and Differential Tumor Immune Infiltrate and PD-1/PD-L1 Expression in Tumors from Patients with Small Cell Lung Cancer and Paraneoplastic Syndromes |
| AACR |
Melanoma, Lung | Novel Multiplexed Digital Pathology Algorithms Identify Superior Predictors of anti-PD-1 Response: A Real World Study |
| Tri-Con |
Breast | MHC-II expression drives a unique pattern of adaptive resistance to antitumor immunity through receptor checkpoint engagement. |
| ASCO-SITC |
Breast | Breast tumor-specific MHC-II expression drives a unique pattern of adaptive resistance to antitumor immunity through MHC-II receptor checkpoint engagement. |
| SABCS |
DLBCL | Clinical significance of PD-1 and PD-L1 expression and ongoing interaction in the tumor microenvironment in diffuse large B cell lymphoma (DLBCL) treated with R-CHOP |
| ASH |
NSCLC | Quantitative Spatial Profiling of PD-1/PD-L1 Interaction Predicts Response to Adjuvant Chemotherapy in Early Stage Non–Small-Cell Lung Cancer |
| IASLC |
Melanoma | Chronic Granulomatous Dermatitis Induced by Talimogene Laherparepvec Therapy of Melanoma Metastases | Journal of Cutaneous Pathology | ASCO |
Solid | Immuno-Oncology biomarker assessment by novel digital imaging algorithms based on AQUA Technology |
| NSH |
Breast | Multiplexed ion-beam imaging (MIBI) analysis for quantitation of protein expression on cancer tissue sections | Laboratory Investigation |
|
Melanoma | Unique biomarker signatures identified by novel quantitative immunohistochemistry algorithms predict outcomes to PD-1 blockers in metastatic melanoma patients |
| Immuno-Oncology Summit |
Melanoma | Inflammatory melanoma in transit metastases with complete response to talimogene laherparepvec. | JAAD Case Reports | ASCO |
Melanoma | Quantitative spatial profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 predicts improved outcomes to anti-PD-1 in metastatic melanoma |
| ASCO |
Testicular | Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling. | OncoImmunology | ASCO |
Renal | Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic Renal Medullary Carcinoma | Journal for Immunotherapy of Cancer | ASCO |
Melanoma | Novel quantitative multiplexed PD-1/PD-L1 immunohistochemistry test provides superior prediction of treatment response in melanoma patients |
| AACR |
Solid Tumor | Novel automated quantitative analysis (AQUA) algorithms for reproducible assessment of PD1-PD-L1 interaction and immune cell subsets by multiplex fluorescence immunohistochemistry in cancer immunotherapy trials. |
| Tri-Con |
ALL | Quantitative multiplexed immunohistochemistry assays for exploring CAR modified T cells and checkpoint inhibitors in lymphoma trials |
| ASH |
CRC | Influence of tumor microenvironment on prognosis in colorectal cancer: Tissue architecture-dependent signature of endosialin (TEM-1) and associated proteins. | Oncotarget | ASCO |
Breast | In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients. | PLoS One | ASCO |
Breast | Development of a binary diagnostic immunofluorescence assay by AQUA® technology for accurate detection of HER-2 levels in breast cancer specimens. |
| AACR |
Breast | Evaluation of HER2 RNA and Protein Levels in a Large Cohort of Breast Cancer Specimens to Support Development of a Diagnostic Immunofluorescence Assay Quantified by AQUA® Technology. |
| AACR |
Breast | Development of a clinical targeted next generation sequencing test for challenging formalin-fixed paraffin-embedded (FFPE) cancer samples |
| AACR |
Breast | Comparison of HER2 and Phospho-HER2 Expression between Biopsy and Resected Breast Cancer Specimens Using a Quantitative Assessment Method | PLoS One | ASCO |